Alberta has become the latest Canadian province to add Humira (adalimumab) to the list of products covered by its biosimilar switching program, following similar recent moves by British Columbia and New Brunswick.
Having introduced its biosimilar switching program back in 2019 – just months after fellow province British Columbia (Also see "